Nexus Pharmaceuticals announces the US availability of its Sodium Nitroprusside Injection. It is available as a single dose vial containing 50 mg per 2 mL (25 mg/mL) and is an AP-rated generic equivalent of Nitropress. The Sodium Nitroprusside Injection is indicated for the immediate reduction of blood pressure for adult and pediatric patients in hypertensive crisis. The product is also indicated for producing controlled hypotension in order to reduce bleeding during surgery and for the treatment of acute congestive heart failure.